|
|
 |
 Hank Plain serves as an active Director and Advisor of early stage medical device companies, providing expertise in founding, funding, product development and operational management. In July 2000, Mr. Plain joined The Foundry, Inc. as Vice Chairman. Mr. Plain was Chairman of the Board of Embolic Protection, Inc., helping to negotiate the acquisition of EPI by Boston Scientific in 2001. He was also a Director of TransVascular, Inc., which was acquired by Medtronic in 2003.
From 1993 until May 2002, Mr. Plain was President and CEO of Perclose. He led Perclose from the product concept stage through product development, regulatory approvals and successful market launch to become the worldwide leader in vascular access site closure devices with over $100 million in sales in 2000. Mr. Plain successfully directed Perclose through an IPO, a secondary offering and acquisition by Abbott Laboratories in November 1999.
Prior to joining Perclose, Mr. Plain was with Eli Lilly and Company for 12 years. Mr. Plain is Chairman of the Board of Directors for Emphasys Medical, Satiety and Access Closure. He is a Director of Acclarent, Ardian, Cabochon Aesthetics, Cierra, The Foundry, and the Pacific Foundation for Cardiovascular Research. |
